Skip to Content

'
Yasuhiro Oki, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2012
Phone: 713-792-2860

Education & Training

Degree-Granting Education

1998 Faculty of Medicine, University of Tokyo, Tokyo, Japan, MD, Medicine

Postgraduate Training

7/2003-6/2006 Clinical Fellowship, Medical Oncology and Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, Robert A. Wolff
7/2000-6/2003 Clinical Residency, Internal Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY, Ethan Fried
4/1998-3/2000 Clinical Residency, Internal Medicine, Toranomon Hospital, Tokyo, Japan, Yoshitomo Muto

Board Certifications

10/2008 American Board of Hematology
10/2006 American Board of Medical Oncology
8/2003 American Board of Internal Medicine

Experience/Service

Academic Appointments

Chief Physician (09/2007-08/2010), Aichi Cancer Center, Nagoya, Japan, 9/2006-8/2010

Institutional Committee Activities

Member, Clinical Research Committee (CRC), 9/2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 6/1/2014. e-Pub 4/7/2014. PMID: 24721592.
2. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood 123(20):3095-100, 5/15/2014. e-Pub 3/20/2014. PMID: 24652992.
3. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. Br J Haematol 165(1):146-7, 4/2014. e-Pub 12/16/2013. PMID: 24329994.
4. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/6/2014. PMID: 24386943.
5. Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol 45(2):421-6, 2/2014. PMID: 24439229.
6. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 12/15/2013. e-Pub 10/4/2013. PMID: 24097867.
7. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 54(12):2631-8, 12/2013. e-Pub 5/7/2013. PMCID: PMC3827734.
8. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
9. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol 163(1):123-6, 10/2013. e-Pub 6/25/2013. PMID: 23795711.
10. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. e-Pub 4/2013. PMID: 23545991.
11. Kato H, Yamamoto K, Oki Y, Ine S, Taji H, Chihara D, Kagami Y, Seto M, Morishima Y. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas. Leukemia 27(8):1792, 8/2013. PMID: 23921999.
12. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 7/2013. e-Pub 4/17/2013. PMID: 23590726.
13. Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. A phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci 103(10):1839-47, 10/2012. e-Pub 9/2012. PMID: 22816487.
14. Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 12(5):623-32, 5/2012. e-Pub 3/2012. PMID: 22428917.
15. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. e-Pub 2/2012. PMCID: PMC3359733.
16. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/2012. PMID: 22383790.
17. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 12/2011. PMID: 22033282.
18. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, de Castro Faria S, Jeffrey Medeiros L, Ivy P, Younes A. Clinical Experience with the Heat Shock Protein-90 inhibitor, Tanespimycin (17AAG), in Patients with Relapsed Lymphoma. Leuk Lymphoma. e-Pub 10/2011. PMID: 21988665.
19. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. e-Pub 7/2011. PMID: 21745170.
20. Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 4(3):245-52, 6/2011. PMID: 21668391.
21. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, Morishima Y. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol 93(4):502-8, 4/2011. e-Pub 4/2011. PMID: 21512731.
22. Estécio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res 20(10):1369-82, 10/2010. e-Pub 8/2010. PMCID: PMC2945186.
23. Kato H, Yamamoto K, Matsuo K, Oki Y, Taji H, Kuwatsuka Y, Seto M, Kagami Y, Morishima Y. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol 21(8):1699-705, 8/2010. e-Pub 2/2010. PMID: 20172906.
24. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep 5(3):135-9, 7/2010. PMID: 20490723.
25. Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol 84(6):493-8, 6/2010. e-Pub 2/2010. PMID: 20148943.
26. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605-13, 2/2010. e-Pub 12/2009. PMCID: PMC2815995.
27. Chihara D, Kagami Y, Oki Y, Kato H, Onoda H, Ine S, Taji H, Yamamoto K, Morishima Y. R-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol 84(1):84-6, 1/2010. e-Pub 9/2009. PMID: 19737307.
28. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 50(12):1999-2004, 12/2009. PMID: 19860627.
29. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 11/2009. e-Pub 9/2009. PMID: 19770379.
30. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881-8, 6/2009. e-Pub 5/2009. PMID: 19470736.
31. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 81(6):448-53, 12/2008. e-Pub 8/2008. PMID: 18691256.
32. Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y, Morishima Y. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49(7):1345-51, 7/2008. PMID: 18452099.
33. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111(4):2382-4, 2/2008. e-Pub 11/2007. PMCID: PMC2234065.
34. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/2008. PMID: 18085611.
35. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 99(1):179-84, 1/2008. e-Pub 11/2007. PMID: 17991293.
36. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 48(9):1869-71, 9/2007. PMID: 17786728.
37. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics 63(2):429-36, 6/2007. PMID: 17688495.
38. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109(5):899-906, 3/2007. PMID: 17236224.
39. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 92(2):269-70, 2/2007. PMID: 17296586.
40. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/2007. PMID: 17133412.
41. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/2007. e-Pub 8/2006. PMID: 16882708.
42. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 91(8):1147-8, 8/2006. e-Pub 7/2006. PMID: 16870548.
43. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 66(10):5077-84, 5/2006. PMID: 16707430.
44. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2/2006. e-Pub 8/2005. PMID: 16123215.
45. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370-3, 11/2005. e-Pub 7/2005. PMCID: PMC1895065.
46. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-7, 8/2005. PMID: 15973667.

Invited Articles

1. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 49(5):883-9, 5/2008. PMID: 18452104.
2. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 86(4):306-14, 11/2007. PMID: 18055336.
3. Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol 61(2):140-52, 2/2007. e-Pub 10/2006. PMID: 17023173.
4. Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 1(2):169-82, 5/2006. PMID: 18473969.
5. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines 3(4):403-11, 8/2004. PMID: 15270645.

Editorials

1. Oki Y, Younes A. Endothelial progenitor cells in non-Hodgkin's lymphoma. Haematologica 92(4):433-4, 4/2007. PMID: 17488651.

Abstracts

1. Takahashi, K, Sivina, M, Oki, Y, Fayad, LE, Neelapu, SS, Kwak, LW, Xiao, L, Huang, X, Fu, K, Chan, WC, Vose, JM, Kantarjian, HM, Keating, M. Burger, JA,. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 120 (#2709), 12/2012.
2. Oki Y,Chuang H,Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad LE, Hagemeister FB , Rodriguez A, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstract) 120(21):1529 (#1529), 12/2012.

Letters to the Editor

1. Oki Y, Copeland A, Hagemeister F, Fayad L, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171 - 2, 3/2012.
2. Oki Y, Kishi Y, Kami M. Philadelphia chromosome-positive acute lymphoblastic leukemia in children. N Engl J Med 343(14):1043, 10/2000.
3. Oki Y, Kami M, Muto Y. Long-term survival after bone marrow transplantation. N Engl J Med 341(18):1394; author reply 1395, 10/1999. PMID: 10577087.

Grant & Contract Support

Title: Identification of genes that are modified by potent heat shock protein inhibitor AUY922 in patients with lymphoma
Funding Source: IRG Grant
Role: Principal Investigator
Duration: 2013
 
Title: Epigenetic analysis of non-Hodgkin lymphoma.
Funding Source: Japan Society for the Promotion of Science
Role: Principal Investigator
Duration: 2008 - 2009

Last updated: 7/15/2014